<table>
<thead>
<tr>
<th>Title</th>
<th>Cyclic AMP-dependent protein kinase-independent angiotensin II-induced inhibition of calcium current in hamster submandibular ganglion neurons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Endoh, T; Abe, M; Suzuki, T</td>
</tr>
<tr>
<td>Journal</td>
<td>Bulletin of Tokyo Dental College, 43(2): 95-99</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10130/313">http://hdl.handle.net/10130/313</a></td>
</tr>
</tbody>
</table>
Short Communication

CYCLIC AMP-DEPENDENT PROTEIN KINASE-INDEPENDENT ANGIOTENSIN II-INDUCED INHIBITION OF CALCIUM CURRENT IN HAMSTER SUBMANDIBULAR GANGLION NEURONS

TAKAYUKI ENDOH, MITSUHiro ABE and TAKASHI SUZUKI

Department of Physiology, Tokyo Dental College, 1-2-2 Masago, Mihama-ku, Chiba 261-8502, Japan

Received 6 March, 2002/ Accepted for Publication 25 March, 2002

Abstract

In a previous study, we demonstrated that angiotensin II (Ang II) inhibited voltage-dependent calcium channels (VDCCs) currents (I_{Ca}) in hamster submandibular ganglion (SMG) neurons. In sinoatrial node cells, it has been reported that Ang II inhibits I_{Ca} by suppressing cyclic AMP production. In this study, to investigate the possible involvement of a cyclic AMP-cyclic AMP dependent protein kinase (PKA) pathway in the Ang II-induced inhibition of I_{Ca}, effects of Ang II were examined in SMG neurons after treatment with an activator and inhibitor of PKA. Neither pretreatment of neurons with membrane permeable cyclic AMP nor intracellular dialysis of PKA blocker attenuated the Ang II-induced inhibition of I_{Ca}. These results indicate that Ang II inhibited I_{Ca} via a cyclic AMP-PKA-independent mechanism in SMG neurons.

Key words: Hamster submandibular ganglion neurons—Voltage-dependent calcium channels—Angiotensin II—Cyclic AMP—Protein kinase A

INTRODUCTION

Angiotensin II (Ang II), one of the main active peptides of the renin-angiotensin system, exerts its multiple functions, including drinking, vasopressin and oxytocin release, natriuresis, cardiovascular, endocrine and neuronal targets. This peptide is one of the most important vasoconstrictive hormones but is also known to act as a neuromodulator and a neurotransmitter in the central and peripheral nervous systems. These actions of Ang II involve modulation of membrane ion channel currents and neuronal activity.

It is well known that cyclic AMP-cyclic AMP dependent protein kinase (PKA) pathways are the most important second messenger pathways which mediate hormone-ion channel regulation. Intracellular Ca^{2+}, which acts as a second messenger, can interact with cyclic AMP, and diacylglycerol (DAG)-protein kinase C (PKC), which is another important second messenger, interacts with the cyclic AMP-PKA pathways.

It has been reported that Ang II receptors cause inhibition of PKA through inhibition of
adenyl cyclase and reduction in cyclic AMP in various tissues. Additionally, it has been demonstrated that Ang II inhibits ICa by suppressing cyclic AMP production in sinoatrial node cells.

We previously reported that Ang II, mediated via Ang II type 1 (AT1) receptors, inhibits voltage-dependent calcium channels (VDCCs) currents (ICa) in submandibular ganglion (SMG) neurons. It remains unclear, however, whether cyclic AMP-PKA pathways are mediated in the Ang II-induced inhibition of ICa in this neuron. Thus, the purpose of the present study was to examine the contribution of cyclic AMP-PKA pathways in the Ang II-induced inhibition of ICa in the SMG neuron.

MATERIALS AND METHODS

Experiments were conducted according to the guidelines for the treatment of experimental animals at Tokyo Dental College. SMG neurons from hamsters were acutely dissociated with a modified version of the method described previously. In brief, SMG neurons were isolated from 4–6 week-old hamsters and maintained in Ca2+-free Krebs solution of the following composition (in mM): 136 NaCl, 5 KCl, 3 MgCl2·6H2O, 10.9 glucose, 11.9 NaHCO3 and 1.1 NaH2PO4·2H2O. The neurons were treated with collagenase type I (3 mg/ml in Ca2+-free Krebs solution; Sigma, St. Louis, MO, U.S.A.) for 50 min at 37°C, followed by incubation in trypsin type I (1 mg/ml in Ca2+-free Krebs solution; Sigma, St. Louis, MO, U.S.A.) for an additional 10 min. The supernatant was replaced with normal Krebs solution of the following composition (in mM): 136 NaCl, 5 KCl, 2.5 CaCl2, 0.5 MgCl2·6H2O, 10.9 glucose, 11.9 NaHCO3 and 1.1 NaH2PO4·2H2O. Neurons were then plated onto poly-l-lysine (Sigma)-coated glass coverslips.

Voltage-clamp recordings were conducted using the whole-cell configuration of the patch clamp technique. Fabricated recording pipettes (2–3MΩ) were filled with an internal solution with the following composition (in mM): 100 CsCl, 1 MgCl2, 10 HEPES, 10 BAPTA, 3.6 MgATP, 14 tris-phosphocreatine, 0.1 GTP, and 50 U/ml creatine phosphokinase. The pH was adjusted to 7.2 with CsOH. After the formation of a giga seal, in order to record ICa, the external Krebs solution was replaced by solution containing the following (in mM): 67 cholinechloride, 100 tetraethylammonium chloride, 5.3 KCl, 5 CaCl2 and 10 HEPES. The pH was adjusted to 7.4 with Tris base. Command voltage protocols were generated with a computer software pCLAMP version 8 (Axon Instruments, Union City, CA, U.S.A.) and transformed to an analogue signal using a DigiData 1200 interface (Axon Instruments, Union City, CA, U.S.A.). The command pulses were applied to the cell through an L/M-EPC7 amplifier (HEKA Elektronik, Lambrecht, Germany). The currents were recorded with the amplifier and a computer software pCLAMP 8 acquisition system.

All data analyses were performed using the pCLAMP 8 acquisition system. Statistical analyses were made by Student t-test. Probability (p) values of less than 0.05 were considered significant.

Ang II was purchased from Peptide Institute. Losartan was a gift from Merck & Co., Inc. 8-(4-chlorophenylthio)-adenosine 3':5'- cyclic monophosphate (CPT-cAMP) was purchased from Sigma, St. Louis, MO, U.S.A. The PKA inhibitor peptide, PKI (5–24), was purchased from BIOMOL Research Laboratories Inc. (Plymouth, PA, U.S.A.).

RESULTS

An example of the effects of Ang II and AT1 receptor antagonist, losartan, on ICa is shown in Fig. 1 (A). Application of 1 μM Ang II inhibited ICa from −2,408 pA to −1,160 pA (51.8% inhibition) in this neuron. 1 μM losartan completely antagonized the inhibitory effect of Ang II.

To evaluate the possible contribution of PKA to the AngII-induced inhibition of ICa,
Fig. 1 (A) Effects of Ang II and losartan on $I_{Ca}$. Superimposed $I_{Ca}$ traces were recorded using a voltage protocol at the times indicated in the time course graph (right). Open points in the graph indicate $I_{Ca}$. Ang II (1 μM) and losartan (1 μM) were bath applied during the times indicated by the filled and open bars, respectively.

(B) Effects of Ang II on $I_{Ca}$ in a neuron pretreated with CPT-cAMP (10 μM for 10 min).

(C) Effects of Ang II on $I_{Ca}$ in the presence of PKI (5–24) (20 μM for 10 min) contained in the recording pipette.
the effects of Ang II on $I_{Ca}$ in neurons treated with CPT-cAMP (10 µM for 10 min), membrane permeable cyclic AMP, were investigated. We have previously demonstrated that this compound has a sufficient effect to cause the saturation of intracellular cyclic AMP levels. As shown in Fig. 1 (B), Ang II-induced inhibition of $I_{Ca}$ was not affected by CPT-cAMP treatment. In addition, intracellular dialysis of PKI (5–24) (20 µM for 10 min), PKA inhibitor, also did not attenuate the Ang II-induced inhibition of $I_{Ca}$ as shown in Fig. 1 (C).

The data showing the effects of altering PKA activity and antagonizing AT$_1$ receptors are summarized in Fig. 2. On average, the Ang II-induced inhibition of $I_{Ca}$ was 32.1 ± 2.7% (n = 9) for control, 7.6 ± 1.5% (n = 7) for neurons treated with losartan, 32.7 ± 4.7% (n = 5) for the neurons treated with CPT-cAMP, and 25.6 ± 3.9% (n = 5) when the recording pipette was filled with PKI (5–24).

**DISCUSSION**

The present results show that Ang II inhibited $I_{Ca}$ by a cyclic AMP-PKA pathway-independent mechanism. In contrast, there is considerable evidence that Ang II receptors cause inhibition of cyclic AMP-PKA through inhibition of adenylyl cyclase and reduction in cyclic AMP. This evidence raises several questions: (1) which processes are absent in Ang II-induced inhibition of $I_{Ca}$ in SMG?; (2) are cyclic AMP-PKA pathways between AT$_1$ receptors and VDCCs possibly absent in SMG?; and (3) is there a possible lack of AT$_1$ receptors that is selectively regulating cyclic AMP-PKA pathways in SMG?

Various reports have demonstrated the distinct second messenger pathways in the Ang II-induced ion channel modulations: for instance, PKC pathways and calcium/calmodulin-dependent protein kinase II (CaM KII) pathways in the central nervous system (CNS) neurons, Ras/Raf/mitogen-activated protein (MAP) kinase pathways and Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways, Fos-regulating kinase and c-Jun NH$_2$-terminal kinase.

The present data do not allow us to deduce the exact mechanism by which intracellular pathways may alter VDCCs function. It will be important in future experiments to determine what second messenger pathways contribute to the Ang II-induced inhibition of $I_{Ca}$ in SMG neurons.

**ACKNOWLEDGEMENTS**

This work was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (No. 12671816).

**REFERENCES**

99AT1 RECEPTOR PATHWAY IN GANGLION NEURON


Reprint requests to:
Dr. Takayuki Endoh
Department of Physiology,
Tokyo Dental College,
1-2-2 Masago, Mihama-ku,
Chiba 261-8502, Japan